Advertisement

Topics

Simulations Plus Reports FY2017 and Fourth Quarter FY2017 Financial Results

16:01 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Full Fiscal Year Pharmaceutical Software and Services Revenues Up 20.9%; Earnings per share of $0.33, up 14.9% over prior year Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmac...

Other Sources for this Article

Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com

NEXT ARTICLE

More From BioPortfolio on "Simulations Plus Reports FY2017 and Fourth Quarter FY2017 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...